BIONET CORP. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 66.4 TWD | -4.32% |
|
+12.93% | +14.29% |
| 03-19 | BIONET Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | BIONET Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
| Sales 2022 | 980M 30.11M 2.41B | Sales 2023 | 1.13B 34.63M 2.77B | Capitalization | 2.74B 84.08M 6.72B |
|---|---|---|---|---|---|
| Net income 2022 | 38M 1.17M 93.35M | Net income 2023 | 78M 2.4M 192M | EV / Sales 2022 | 1.67 x |
| Net cash position 2022 | 423M 13.01M 1.04B | Net cash position 2023 | 862M 26.49M 2.12B | EV / Sales 2023 | 1.66 x |
| P/E ratio 2022 |
54.9
x | P/E ratio 2023 |
35
x | Employees | - |
| Yield 2022 |
1.59% | Yield 2023 |
1.22% | Free-Float | 70.62% |
More Fundamentals
* Assessed data
More news
| 1 day | -4.32% | ||
| 1 week | +12.93% | ||
| Current month | +6.41% | ||
| 1 month | +5.06% | ||
| 3 months | +12.35% | ||
| 6 months | +12.93% | ||
| Current year | +14.29% |
1 week
60.90
74.00
1 month
58.0074.00
Current year
56.5074.00
1 year
55.6075.70
3 years
35.1075.70
5 years
23.6075.70
10 years
19.2575.70
| Managers | Title | Age | Since |
|---|---|---|---|
Tien Lai Liu
CEO | Chief Executive Officer | - | 31/08/06 |
Pei Yi Liu
DFI | Director of Finance/CFO | - | 22/03/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shao Hua Huang
BRD | Director/Board Member | 75 | 20/11/06 |
Cheng Hsien Tsai
CHM | Chairman | - | 31/07/00 |
Wen Cheng Chang
BRD | Director/Board Member | - | 10/04/03 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 66.4 | -4.32% | 2,967,898 |
| 25/04/24 | 69.4 | +9.98% | 1,205,747 |
| 24/04/24 | 63.1 | -1.56% | 403,120 |
| 23/04/24 | 64.1 | +5.43% | 1,136,988 |
| 22/04/24 | 60.8 | +3.40% | 574,824 |
End-of-day quote Taipei Exchange, April 25, 2024
More quotes
BIONET CORP. is a Taiwan-based company principally engaged in the storage and application of hematopoietic stem cells. The Companyâs main products include umbilical cord blood stem cells, mesenchymal stem cells, adult peripheral blood stem cells and others. The Company also provides precision medical application, prenatal testing and genetic testing services. The Company operates its businesses mainly in domestic market.
| 1st Jan change | Capi. | |
|---|---|---|
| +14.29% | 96.27M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- 1784 Stock
